Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma
Yanli Cai
BackgroundGlioblastoma (GBM) remains a lethal brain tumor with limited therapeutic options and near-universal recurrence. Drug repurposing offers a practical strategy, but pleiotropic compounds require systematic target triage to yield actionable and testable vulnerabilities.MethodsWe integrated GBM transcriptomic dysregulation with curated chlorpromazine (CPZ)-associated targets to define drug–disease intersecting genes, constructed a protein–protein interaction network, and developed an outcom